Everything below concerns thymosin beta-4. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2026-08-01. Numbers and descriptions here follow the published literature rather than marketing material.
TB-500 is a synthetic heptapeptide with the sequence Ac-LKKTETQ. It corresponds to a short N-terminal region of thymosin beta-4, a 43-amino-acid protein found in many cell types. The fragment contains an actin-binding motif, which is one reason it appears in laboratory studies of cell migration and cytoskeletal dynamics. TB-500 is not the full-length protein and is produced as a research chemical rather than an approved therapeutic agent. Its molecular weight is approximately 889 Da.
Several names appear in scientific and commercial contexts for this peptide. The label TB-500 is informal and does not follow standard biochemical nomenclature. Research articles more often describe the compound as a thymosin beta-4 fragment, Tβ4 fragment, or by its sequence Ac-LKKTETQ. Confusing TB-500 with full-length thymosin beta-4 can lead to incorrect assumptions about activity because the fragment lacks the remaining residues of the parent protein. The relationship between fragment and parent protein remains an active area of study.
Regulatory status differs by country, but TB-500 is not an approved pharmaceutical in major jurisdictions. It is commonly sold as a research chemical for laboratory use, which places responsibility for identity and purity on the supplier and the laboratory. Published human data are limited, and most reports involve preclinical models or cell culture. Questions about whether the fragment mimics all actions of thymosin beta-4, and under which conditions, remain open. Independent verification of any material is therefore a practical requirement in research settings.
Thymosin beta-4 is a 43-residue actin-binding protein found in most mammalian cell types, where it participates in cytoskeletal regulation and cell migration. TB-500 represents only a short fragment of that protein and does not include the remaining residues. Whether the isolated fragment reproduces the full range of activities reported for the intact protein remains an open question. Researchers commonly treat the two as related but distinct entities when comparing results.
Published work involving this sequence spans actin-binding assays, cell-migration studies, wound-healing models, and cardiovascular or musculoskeletal experiments. Much of the biological rationale derives from in vitro systems and animal models, and the number of controlled human studies is small. Reported outcomes vary across preparations, doses, and routes, which complicates comparison between studies. Reviews generally describe the evidence base as preliminary rather than settled. Mechanistic explanations are often proposed by analogy to the parent protein rather than demonstrated directly.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C38H68N10O14 | Calculated for the acetylated heptapeptide |
| Molecular weight | ~889 Da | Monoisotopic mass approximately 889.0 Da |
| Amino acid sequence | Ac-LKKTETQ | N-terminal acetylated seven-residue peptide |
| Appearance | White to off-white powder | Typically supplied as a lyophilized solid |
| Solubility class | Water-soluble | Peptides of this size generally dissolve in aqueous media |
TB-500 refers to a synthetic peptide fragment derived from the actin-binding region of thymosin beta-4, a protein present in most mammalian cells. The full protein contains forty-three amino acids, while the commonly sold fragment is a much shorter acetylated sequence, often cited as LKKTETQ. The fragment retains part of the actin-binding motif but lacks the remainder of the parent protein. Material sold under this name is usually lyophilized powder intended for laboratory research, and it is not a finished pharmaceutical product.
Proposed activity centers on actin sequestration and on the movement of cells during repair processes. In cell culture and animal models, the fragment has been associated with migration, tube formation, and tissue remodeling. These observations are frequently described as preliminary, because most published work uses rodent or in vitro systems rather than controlled human trials. Whether the short fragment reproduces the effects of the full protein remains an open question, and the relationship between dose, route, and measured outcome is not well characterized.
The compound circulates in the literature as a research reagent rather than an approved therapeutic. Regulatory agencies in several countries have not authorized it for medical use, and sporting bodies list related thymosin beta-4 peptides among prohibited substances. Suppliers typically market it with a purity figure and a certificate of analysis, while peer-reviewed clinical reports remain sparse. Discussions therefore often separate laboratory findings from anecdotal reports, and reviewers tend to note the small size and methodological limits of the available studies.
The designation TB-500 circulates in laboratory and catalog contexts without a single agreed definition. Most product listings apply it to an N-terminally acetylated seven-residue fragment of thymosin beta-4, while other listings attach the same label to the full 43-residue protein. Because the term is commercial rather than systematic, two entries bearing identical names may describe different molecules. Any documentation should therefore state which sequence a given sample is claimed to contain.
The fragment most often associated with the name carries the sequence Ac-LKKTETQ, matching residues 17 through 23 of thymosin beta-4. That region holds the actin-binding motif responsible for much of the parent protein's biochemical activity. Apart from N-terminal acetylation the peptide is unmodified and contains no disulfide bonds, so it shows little ordered secondary structure in solution. Full-length thymosin beta-4 is instead a 43-residue polypeptide of roughly 4.9 kDa found widely across mammalian cell types.
Material sold under this label typically arrives as a freeze-dried powder in a sealed vial with a certificate of analysis. Such certificates usually report reversed-phase chromatography purity plus a mass confirmation, and stated purities commonly sit between 95 and 99 percent. Counter-ion identity, residual trifluoroacetate, water content, and peptide net weight are separate specifications that a certificate may or may not include. A purity figure alone does not establish sequence identity, so independent mass verification remains the practical check.
Thymosin beta-4 itself is a small, widely expressed protein that sequesters monomeric actin and participates in cell migration, angiogenesis, and tissue repair. Researchers have examined the shortened fragment as a possible mimic of some of these activities, reasoning that the actin-binding motif lies within the first few residues. Binding to monomeric actin has been observed in cell-free systems. Whether the fragment reproduces the broader effects of the full protein in living tissue remains an open question, and findings from animal models are frequently cited without a clear bridge to human physiology.
Discussion of TB-500 appears in several distinct literatures that rarely cite one another. Peer-reviewed studies usually describe in vitro assays or small animal experiments and are cautious about extrapolation. Veterinary and sports communities circulate anecdotal reports with limited methodological detail. Commercial listings add a third layer, often using the name interchangeably with thymosin beta-4 even though the two molecules differ in size and sequence. Regulatory status varies by country, and the compound is not a licensed medicine in most jurisdictions, so readers comparing sources should check which molecule and which purity each source actually describes.
==== Iraq ==== Over 50 think tanks have emerged in Iraq, particularly in the Kurdistan Region. Iraq's leading think tank is the Middle East Research Institute (MERI), based in Erbil. MERI is an independent non-governmental policy research organization, established in 2014 and publishes in English, Kurdish, and Arabic. It was listed in the global ranking by the United States's Lauder Institute of the University of Pennsylvania as 46th in the Middle East.
=== Independent (1919-1967) === In 1919, physicist and university lecturer Frederick David Edwards and his father William founded their eponymous business in Camberwell, London, as Edwards Equipment and Services. They sold vacuum pumps to research laboratories from the UK, France, Germany and the USA. When World War II began, German patents were voided in the UK, which meant Edwards was cut off from their suppliers. This led the company to begin manufacturing its own products in 1939. The firm was rebranded W Edwards and Co in 1940, then Edwards High Vacuum International Ltd in 1950, and moved from London to Crawley in 1953. Edwards purchased Italian freeze-drying equipment manufacturer Alto Vuoto SpA in 1954, followed by the Shoreham factory of former subcontractor J H Holmes and Son Ltd in 1958. In the 1960s the firm listed as a public company and suffered from strike actions. Its founder FD Edwards died, and after financial difficulties, the company was sold to BOC.
The Commission had general powers of administration and was particularly "charged with the duty of arranging for the vote and of taking such measures as it may deem necessary to ensure its freedom, fairness, and secrecy. The Commission will have all necessary authority to decide any questions to which the execution of these provisions may give rise. The Commission will make such arrangements as may be necessary for assistance in the exercise of its functions by officials chosen by itself from the local population. Its decisions will be taken by a majority". The Commission was welcomed by the Poles in the region, who hoped that its presence would improve their situation, but petitions were made to remove German officials and the Sicherheitswehr and demanded the official welcoming committee of German officials to show the representatives of the Allies the plight of ethnic Poles. On 18 February 1919, the Allenstein-based commission decreed that the Polish language would gain equal rights to the German language in the region. The commission eventually had to remove both the mayor of Allenstein, Georg Zülch, and an officer of Sicherheitswehr, Major Oldenburg, after a Polish banner at the local consulate of Poland was defaced. The Poles expressed gratitude for Allied protection of Polish rights and underlined their desire for peaceful co-existence with the Germans. In April 1920, during a Polish theatrical performance in Deuthen (Dajtki), near Allenstein, Poles were attacked by pro-German activists.
repeat Any pattern of nucleobases within a nucleic acid sequence which occurs in multiple copies in the same nucleic acid molecule such as a chromosome or within a genome. Repeated sequences are classified according to their length, structure, location, mode of replication, or evolutionary origin. They may be any length, but are often short motifs of less than 100 bases; they may be direct or inverted, and may occur in tandem arrays with the copies immediately adjacent to each other or interspersed with non-repeated sequences. Significant fractions of most eukaryotic genomes consist of repetitive DNA, much of it retroviral in origin, though repeats may also result from errors in normal cellular processes, as with duplications during DNA replication or cell division. Because so many genetic mechanisms depend on the binding or complementing of locally unique sequences, sequences containing or adjacent to repeats are particularly prone to errors in replication and transcription by strand slippage, or to forming problematic secondary structures, and thus repeats are often unstable in the sense that the number of copies tends to expand or diminish stochastically with each round of replication, causing great variation in copy number even between different cells in the same organism. When repeats occur within genes or regulatory elements, these properties often result in aberrant expression and lead to disease. Repeats are also essential for normal genome function in other contexts, as with telomeres and centromeres, which consist largely of repetitive sequences.
Sources: en.wikipedia.org
The origins of the Cossacks are disputed. According to scientific studies, the Y-chromosomal genetic makeup of Zaporozhian, Don, and Kuban Cossacks forms the southern fragment of the East Slavic population, with minimal or no Caucasian or Asian component in their paternal gene pool. However, the term "Cossack" referred to independent horse-riding communities by the Tatars (qazaq or "free men") who inhabited the Pontic–Caspian steppe, north of the Black Sea near the Dnieper River. By the end of the 15th century, the term was also applied to Slavic peasants who had fled to the devastated regions along the lower Dnieper and Don Rivers, where they established their self-governing, cavalry-based communities. Until at least the 1630s, these Cossack groups remained ethnically and religiously autonomous. There were several major Cossack hosts in the 16th century: near the Dnieper, Don, Volga, and Ural Rivers; the Greben Cossacks in Caucasia; and the Zaporozhian Cossacks, mainly west of the Dnieper. It is unclear when people other than the Brodnici and Berladnici (which had a Romanian origin with large Slavic influences) began to settle in the lower reaches of major rivers such as the Don and the Dnieper after the demise of the Khazars. Their arrival was theorized to have been around the 13th century when the Mongols broke the power of the Cumans, who had assimilated the previous population in that region. It is known that immigrant settlers inherited a lifestyle that long pre-dated their presence, including from that of the Cumans and the Circassian Kassaks.
Alpha: Lineage B.1.1.7 emerged in the United Kingdom in September 2020, with evidence of increased transmissibility and virulence. Notable mutations include N501Y and P681H. An E484K mutation in some lineage B.1.1.7 virions has been noted and is also tracked by various public health agencies. Beta: Lineage B.1.351 emerged in South Africa in May 2020, with evidence of increased transmissibility and changes to antigenicity, with some public health officials raising alarms about its impact on the efficacy of some vaccines. Notable mutations include K417N, E484K and N501Y. Gamma: Lineage P.1 emerged in Brazil in November 2020, also with evidence of increased transmissibility and virulence, alongside changes to antigenicity. Similar concerns about vaccine efficacy have been raised. Notable mutations also include K417N, E484K and N501Y. Delta: Lineage B.1.617.2 emerged in India in October 2020. There is also evidence of increased transmissibility and virulence, and changes to antigenicity. Omicron: Lineage B.1.1.529 emerged around Botswana in November 2021. This lineage demonstrated significantly increased transmissibility and changes to antigenicity, and it subsequently dominated all circulating versions of the virus ever since its emergence. Omicron variant BA.3.2 was reported to be widespread across Europe and the US in April 2026. The variant has many changes to the spike protein, but had not been found to be more virulent than other Omicron variants, and existing vaccines protected against it.
== Prognosis == IRIS has a reported mortality rate of 4.5%. Mortality rates vary and depend on the associated OI, degree of immunosuppression, geography, and access to treatment. IRIS affecting the central nervous system has generally been associated with the highest mortality rates (13-75%).
Sources: en.wikipedia.org
TB-500 is a synthetic heptapeptide corresponding to a fragment of thymosin beta-4. It is used in laboratory research and is not an approved drug.
No. Thymosin beta-4 is a 43-amino-acid protein, while TB-500 represents only a short N-terminal segment. The two should not be treated as interchangeable in experimental design.
It is often called a thymosin beta-4 fragment, Tβ4 fragment, or Ac-LKKTETQ. The name TB-500 is mainly a commercial or catalog label rather than a formal chemical name.
No. TB-500 is a short synthetic peptide matching residues 17 to 23 of thymosin beta-4, while the parent protein contains 43 residues. The fragment lacks the rest of the protein sequence, so the two are related but not identical.